Iduronidase and use thereof

By developing novel compounds that stabilize α-L-iduronidase, the problem of poor efficacy of mucosaccharide treatment in the prior art has been solved, the stability and activity of enzymes have been improved, and the treatment of mucosaccharide has been significantly improved. Effects reduce the production of repulsive antibodies.

CN119013006APending Publication Date: 2024-11-22周美吟
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380033993.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-14
Filing Date
2023-04-10
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Existing treatments for mucopolysaccharides, such as enzyme replacement therapy and gene therapy, patients often produce rejective antibodies after long-term treatment, resulting in poor efficacy and difficulty in effectively treating and preventing α-iduronidase activity. The first type of mucopolysaccharide.

Method used

A novel compound was developed to reduce the environmental pressure felt by the enzyme by stabilizing α-L-Idurulonidase, thereby improving the degree of hydrolysis of α-L-Idurulonidic acid at the end of glycosaminoglycans, using in the treatment and prevention of mucosaccharides. The compound has a specific structure, including an Idururuproic/imine Idururuproic group, capable of binding to recombinant human α-Idururuduicase, improving the stability and activity of the enzyme.

Benefits of technology

By improving the stability and activity of α-iduronidase, reducing the accumulation of HS in cells, significantly improving the therapeutic effect of mucopolysaccharides, reducing the production of rejective antibodies, and improving the long-term effectiveness of the treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119013006A_ABST
    Figure CN119013006A_ABST
Patent Text Reader

Abstract

The present disclosure relates to compounds that can stabilize the activity of recombinant human alpha-iduronidase, and to the use of such compounds to treat and / or prevent lyosomal storage disorders (LSD) (e.g., type I mucopolysaccharide). The disclosed compounds have the structure of Formula (I): # imgabs 0 # wherein n is an integer between 0 and 2, X1 is O or-NH, X2 is O,-NH or-NRa wherein Ra is C1-10 alkyl, Y is H or # imgabs 1 # wherein m and p may be 0 or 1, respectively, X3 is O,-NH, methylene or-CH2 (C1-C10) alkyl, and A is aryl, heteroaryl or heterocyclyl with or without one or more substituents selected from halogen, hydroxyl, amino and phosphate, respectively.
Need to check novelty before this filing date? Find Prior Art

Description

Related Application Cross-reference

[0001] This application claims priority to U.S. Provisional Patent Application No. 63 / 330,783, filed on April 14, 2022, the entire contents of which are incorporated herein by reference. Background of the Invention Technical Field

[0003] The present disclosure relates to the treatment of mucopolysaccharidosis, in particular, to novel compounds that can stabilize the activity of recombinant human α-iduronidase (rh-α-DUA), and the use of these novel compounds to treat and / or prevent mucopolysaccharidosis type I (MPSI). Background Art

[0005] Mucopolysaccharidosis (MPS) is a disease caused by insufficient activity of enzymes that catalyze the degradation of specific glycosaminoglycans (GAGs), such as dermatan sulfate (DS) and heparan sulfate (HS). GAGs consist of long, unbranched polysaccharides characterized by repeated disaccharide units. Due to insufficient activity of these enzymes, GAGs accumulate in cells. Lysosomes in the cells of individuals affected by this insufficient enzyme activity will continue to cause permanent tissue damage, thereby affecting the individual's appearance, physical fitness, organ function, and even mental development.

[0006] Each type of mucopolysaccharidosis is distinguished by the enzymes that are affected in the GAG ​​degradation pathway. For example, mucopolysaccharidosis type I (MPSI) is caused by insufficient activity of α-iduronidase (α-DUA), which hydrolyzes the terminal α-iduronic acid of HS. The clinical manifestations of MPSI are related to the amount of residual enzyme activity. There are many ways to treat MSP, most of which focus on enzyme replacement therapy (ERT) or gene therapy to manage the disease process. ERT is to administer a natural or recombinant enzyme produced in vitro (e.g., recombinant human α-iduronidase, rh-α-DUA) to the patient; as for gene therapy, it is to administer a vector that can express the recombinant enzyme in the patient's body. However, patients who receive ERT or gene therapy often develop antibodies against the enzyme used for treatment after long-term treatment, resulting in poor efficacy.

[0007] In view of this, there is an urgent need in the relevant field for an improved method to treat and / or prevent diseases or symptoms caused by a large amount of HS accumulation in the body, especially MPSI. Summary of the invention

[0008] The inventors of the present disclosure have designed and synthesized a variety of novel compounds developed based on iduronic acid / imiduronic acid to stabilize α-L-iduronidase (IDUA) and reduce the environmental stress felt by such enzymes, thereby improving the degree of hydrolysis of terminal α-L-iduronic acid of glycosaminoglycans (e.g., HS). Therefore, these newly synthesized compounds are compounds that are potentially useful for developing drugs that can treat and / or prevent diseases caused by HS accumulation (e.g., MPSI).

[0009] Therefore, the first aspect of the present disclosure is about a novel compound having a structure of formula (I), a pharmaceutically acceptable salt, solvate or stereoisomer thereof, in, n is an integer between 0 and 2; X1 is O or -NH; X2 is O, -NH or -NR a , where R a It is C 1-10 alkyl, Y is H or in m and p can be 0 or 1 respectively; X3 is O, -NH, methylene or -CH2(C 1-10 )alkyl; and A is an aryl group, a heteroaryl group or a heterocyclic group, each having or not having one or more substituents selected from halogen, hydroxyl, amine and phosphate.

[0010] According to a preferred embodiment of the present disclosure, in the compound of formula (I), n is 1, X1 is O, X2 is -NH, and Y is H.

[0011] According to a preferred embodiment of the present disclosure, the compound has a structure of formula (II), in, X1 is O or -NH; X2 is O, -NH or -NR a , where R a It is C 1-10 alkyl; and R1, R2 and R3 can be H or phosphate, respectively.

[0012] According to certain embodiments of the present disclosure, the compound having the structure of formula (II) may be any of the following:

[0013] According to a preferred embodiment of the present disclosure, the compound of formula (II) is

[0014] The second aspect of the present disclosure is to provide a pharmaceutical composition for treating or preventing an individual suspected of having mucopolysaccharidosis type I (MPSI). The pharmaceutical composition comprises an effective therapeutic amount or an effective preventive amount of the compound of formula (I) above, and a pharmaceutically acceptable carrier.

[0015] In terms of the total weight of the pharmaceutical composition, the compound of formula (I) accounts for about 0.1% to 99% of the total weight of the pharmaceutical composition. In certain embodiments, the compound of formula (I) accounts for at least about 1% of the total weight of the pharmaceutical composition. In specific embodiments, the compound of formula (I) accounts for at least about 5% of the total weight of the pharmaceutical composition. In other embodiments, the compound of formula (I) accounts for at least about 10% of the total weight of the pharmaceutical composition. According to other embodiments, the compound of formula (I) accounts for at least about 25% of the total weight of the pharmaceutical composition.

[0016] Preferably, in the compound of formula (I), n is 1, X1 is O, X2 is -NH, and Y is H.

[0017] According to a preferred embodiment of the present disclosure, the compound has a structure of formula (II), in, X1 is O or -NH; X2 is O, -NH or -NR a , where R a It is C 1-10 alkyl; and R1, R2 and R3 can be H or phosphate, respectively.

[0018] According to certain embodiments of the present disclosure, the compound having the structure of formula (II) may be any of the following:

[0019] According to a preferred embodiment of the present disclosure, the compound of formula (II) is

[0020] The present disclosure also relates to a method for treating or preventing a subject suspected of having mucopolysaccharidosis type I (MPSI), comprising administering a recombinant human α-iduronidase (rh-α-DUA) to the subject before, after, or simultaneously with administering the pharmaceutical composition of the present invention.

[0021] The present disclosure also encompasses a kit for treating or preventing an individual suspected of having MPSI type I. The kit comprises at least a first container containing the compound of formula (II) and a second container containing rh-α-DUA.

[0022] One or more embodiments of the present disclosure will be described in detail below. After referring to the following detailed description and the scope of claims, the many accompanying features and advantages of the present disclosure will be easily understood.

[0023] It should be understood that the foregoing general description and the following detailed description are merely exemplary and are intended to further illustrate the claimed invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] The present disclosure and other features, aspects and advantages will become more apparent after referring to the following detailed description of the embodiments, the claims and the accompanying drawings, wherein:

[0025] Figure 1 The results of the rh-α-IDUA stability test of the compound of Example 1 / rh-α-IDUA in GM 1391 fibroblasts, wherein (A) is the result of screening the compound of Example 1 by co-treating cells with rh-α-IDUA (0.1 nM) and compound 12 or 27b (100 μM); (B) is the dose-dependency test of compound 12, 27a or 27b and rh-α-IDUA (1 nM); (C) is the effect of co-treatment of compound 12 and rh-α-IDUA (0.1 nM) on IDUA activity, and (D) is the effect of co-treatment of compound 12 and rh-α-IDUA (0.1 nM) on reducing the amount of intracellular HS. Each data is the average of three replicates + SD, *P<0.05; **P<0.01; ***P<0.001 after analysis of rh-α-IDUA alone by post hoc analysis of variance; and

[0026] Figure 2 The results of the rh-α-IDUA stability test of compound 12 / rh-α-IDUA in GM02846 fibroblasts, where (A) IDUA activity; (B) the result of reducing the amount of HS in cells, each data is the average of three replicates + SD, *P<0.05; **P<0.01; ***P<0.001 after analysis of rh-α-IDUA alone by post hoc analysis of variance. DETAILED DESCRIPTION

[0027] In order to make the description of the contents of the present disclosure more detailed and complete, the following provides an illustrative description of the implementation and specific embodiments of the present invention; however, this is not the only form of implementing or using the specific embodiments of the present invention.

[0028] 1. Definition

[0029] Unless otherwise indicated, when the term "substituted" is used herein to describe a chemical structure or a moiety, it means that one or more hydrogen atoms of the chemical structure or moiety are replaced by another atom, moiety or functional group, and the functional group includes, but is not limited to, -OH, -O(H2PO3), alkyl (e.g., methyl, ethyl, propyl, tert-butyl), alkoxy, alkanoyloxy (e.g., -OAc), alkenyl, aryl, aryloxy, halogen or haloalkyl.

[0030] "Heterocyclyl" refers to a 3- to 10-membered non-aromatic ring system having an atomic group with cyclic carbon atoms, 1 to 4 cyclic heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus and silicon ("3-10 membered heterocyclyl"). In heterocyclyl groups containing one or more nitrogen atoms, the atoms may be attached to carbon atoms or nitrogen atoms as permitted by the valence. A heterocyclyl group may be a single ring ("monocyclic heterocyclyl"), or a fused, bridged or spirocyclic ring system, such as a bicyclic ring system ("bicyclic heterocyclyl"), which may be saturated or partially unsaturated. Cyclic heterocyclyl bicyclic ring systems may include one or more heteroatoms in one or both rings. Heterocyclyl groups include heteroaryl groups. Heterocyclyl also includes cyclic systems in which the cyclic heterocycle is as defined above, fused to one or more carbocyclic rings, where the point of attachment can be on the cyclic carbocyclic or cyclic heterocyclic groups, or cyclic systems in which the cyclic heterocycle is as defined above, fused to one or more aromatic or heteroaromatic groups, where the point of attachment is on the heterocyclic ring, in which case the numbering of carbon atoms within the cyclic heterocyclic ring system is the designated consecutive numbering. Unless otherwise indicated, in each instance the heterocyclyl group may be optionally substituted, i.e., unsubstituted (a "unsubstituted heterocyclyl group") or with one or more substituents (a "substituted heterocyclyl group"). In certain embodiments, the heterocyclyl group is an unsubstituted 3-10 membered heterocyclyl group. In certain embodiments, the heterocyclyl group is a substituted 3-10 membered heterocyclyl group.

[0031] In certain embodiments, a heterocyclic group refers to a 5-10 membered non-aromatic ring system having cyclic carbon atoms and 1-4 cyclic heteroatoms, wherein each heteroatom is selected from the group consisting of nitrogen, oxygen, sulfur, boron, phosphorus and silicon ("5-10 membered heterocyclic group"). In certain embodiments, a heterocyclic group refers to a 5-8 membered non-aromatic ring system having cyclic carbon atoms and 1-4 cyclic heteroatoms, wherein each heteroatom is selected from the group consisting of nitrogen, oxygen and sulfur ("5-8 membered heterocyclic group"). In certain embodiments, a heterocyclic group refers to a 5-6 membered non-aromatic ring system having cyclic carbon atoms and 1-4 cyclic heteroatoms, wherein each heteroatom is selected from the group consisting of nitrogen, oxygen and sulfur ("5-6 membered heterocyclic group"). In some embodiments, the 5-6 membered heterocyclic group has 1-3 cyclic heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur. In certain embodiments, the 5-6 membered heterocyclic group has 1-2 ring heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur. In certain embodiments, the 5-6 membered heterocyclic group has one ring heteroatom selected from the group consisting of nitrogen, oxygen and sulfur.

[0032] Examples of 3-membered heterocyclic groups containing one heteroatom include, but are not limited to, 3-azirdinyl, oxiranyl, thiorenyl. Examples of 4-membered heterocyclic groups containing one heteroatom include, but are not limited to, azetidinyl, oxetanyl, and thietanyl. Examples of 5-membered heterocyclic groups containing one heteroatom include, but are not limited to, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, dihydrothienyl, pyrrolidinyl, dihydropyrrolyl, pyrrole-2,5-dione. Examples of 5-membered heterocyclic groups containing two heteroatoms include, but are not limited to, dioxolanyl, oxasulfuranyl, disulfuranyl, and oxazolidin-2-one. Examples of 5-membered heterocyclic groups containing 3 heteroatoms include, but are not limited to, triazolinyl, oxadiazolinyl, and thiadiazolinyl. Examples of 6-membered heterocyclic groups containing one heteroatom include, but are not limited to, piperidinyl, tetrahydropyranyl, dihydropyridinyl, and thienyl. Examples of 6-membered heterocyclic groups containing two heteroatoms include, but are not limited to, piperazinyl, morpholinyl, dithiyl, and dioxolanyl. Examples of 6-membered heterocyclic groups containing three heteroatoms include, but are not limited to, triazinanyl. Examples of 7-membered heterocyclic groups containing one heteroatom include, but are not limited to, azepanyl, oxepanyl, and thiepanyl. Examples of 8-membered heterocyclic groups containing one heteroatom include, but are not limited to, azocanyl, oxecanyl, and thiocanyl. Examples of 5-membered heterocyclic groups fused to a C6 aromatic ring (also referred to herein as 5,6-bicyclic heterocycles) include, but are not limited to, indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, and benzoxazolinonyl, etc. 6-membered heterocyclic groups fused to an aromatic ring (also referred to herein as 6,6-bicyclic heterocycles) include, but are not limited to, tetrahydroquinolinyl and tetrahydroisoquinolinyl, etc.

[0033] "Aryl" refers to a radical having 6 to 14 carbon atoms and no heteroatoms ("C 6-14 In some embodiments, an aryl group has 6 annular carbon atoms ("C6 aryl"; e.g., phenyl). In some embodiments, an aryl group has 10 annular carbon atoms ("C 10In certain embodiments, an aryl group has 14 ring carbon atoms ("C 14 "Aryl" also includes polycyclic ring systems in which an aromatic ring, as defined above, is fused to one or more carbocyclic or heterocyclic groups, wherein the point of attachment is at the aromatic ring, in which case the numbering of the carbon atoms within the aromatic ring system is designated by consecutive numbering. Unless otherwise indicated, the aromatic group in each instance may be optionally substituted, i.e., unsubstituted ("unsubstituted aromatic") or with one or more substituents ("substituted aromatic"). In certain embodiments, the aromatic group is unsubstituted C 6-14 In certain embodiments, the aromatic group is a substituted C 6-14 Aromatic group.

[0034] "Heteroaryl" refers to a 5-10 membered monocyclic ring (each heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur) ("5-10 membered heteroaryl") or a bicyclic 4n+2 aromatic ring system (e.g., a ring arrangement with 6 or 10 π electrons shared) having cyclic carbon atoms and 1-4 cyclic heteroatoms within the aromatic ring. The heteroaryl group contains one or more nitrogen atoms, attached to carbon atoms or nitrogen atoms as allowed by the atomic valence. The bicyclic ring system of the heteroaryl group may include one or more heteroatoms within one or both of its rings. "Heteroaryl" also includes a ring system in which a cyclic heteroaryl (as defined above) is fused to one or more carbocyclic or heterocyclic groups, wherein the point of attachment is on the cyclic heteroaryl, in which case the numbering of the members within the cyclic heteroaryl system is designated by consecutive numbering. "Heteroaryl" also includes cyclic heteroaryl (as defined above) fused to one or more aromatic ring systems, where the point of attachment is on the aromatic or heteroaromatic ring, in which case the member number is assigned to all members of the ring fusion (aromatic / heteroaryl). For bicyclic heteroaryl groups where one ring does not contain heteroatoms (e.g., indolyl, quinolyl, carbazolyl, etc.), the point of attachment can be on either ring, i.e., on the heteroatom ring (e.g., 2-indolyl), or on the heteroatom-free ring (e.g., 5-indolyl).

[0035] In certain embodiments, a heteroaryl group is a 5-10 membered aromatic ring system having cyclic carbon atoms and 1-4 heteroatoms ("5-10 membered heteroaryl"), wherein each heteroatom can be nitrogen, oxygen, or sulfur. In certain embodiments, a heteroaryl group is a 5-8 membered aromatic ring system having carbon atoms and 1-4 heteroatoms, wherein each heteroatom can be nitrogen, oxygen, or sulfur ("5-8 membered heteroaryl"). In certain embodiments, a heteroaryl group is a 5-6 membered aromatic ring system having carbon atoms and 1-4 heteroatoms, wherein each heteroatom can be nitrogen, oxygen, or sulfur ("5-6 membered heteroaryl"). In certain embodiments, a 5-6 membered heteroaryl group has 1-3 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur. In certain embodiments, a 5-6 membered heteroaryl group has 1-2 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur. In some embodiments, a 5-6 membered heteroaryl group has 1 heteroatom selected from the group consisting of nitrogen, oxygen, and sulfur. Unless otherwise indicated, each instance of a heteroaryl group may contain optional substituents, i.e., no substituents ("unsubstituted heteroaryl"), or one or more substituents ("substituted heteroaryl"). In certain embodiments, a heteroaryl group is an unsubstituted 5-14 membered heteroaryl. In certain embodiments, a heteroaryl group is a substituted 5-14 membered heteroaryl.

[0036] Examples of 5-membered heteroaryl groups containing one heteroatom include, but are not limited to, pyrrolyl, furanyl, and thienyl. Examples of 5-membered heteroaryl groups containing two heteroatoms include, but are not limited to, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl. Examples of 5-membered heteroaryl groups containing 3 heteroatoms include, but are not limited to, triazolyl, oxadiazolyl, and thiadiazolyl. Examples of 5-membered heteroaryl groups containing 4 heteroatoms include, but are not limited to, tetrazolyl. Examples of 6-membered heteroaryl groups containing one heteroatom include, but are not limited to, pyridyl. Examples of 6-membered heteroaryl groups containing two heteroatoms include, but are not limited to, pyridazinyl, pyrimidinyl, and pyrazinyl. Examples of 6-membered heteroaryl groups containing 3 or 4 heteroatoms include, but are not limited to, triazinyl and tetrazinyl. Examples of 7-membered heteroaryl groups containing one heteroatom include, but are not limited to, azepinyl, oxepinyl, and thiepinyl. Examples of 5,6-bicyclic heteroaryl groups include, but are not limited to, indolyl, isoindolyl, indazolyl, benzotriazolyl, benzothiophenyl, isobenzothiophenyl, benzofuranyl, benzoisofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzoxadiazolyl, benzothiazolyl, benzisothiazolyl, benzthiadiazolyl, indolizinyl, and purinyl. Examples of 6,6-bicyclic heteroaryl groups include, but are not limited to, naphthyridinyl, pteridine, quinolinyl, isoquinolinyl, cinnolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl.

[0037] "Halo" or "halogen" refers to fluorine (-F), chlorine (-Cl), bromine (-Br), or iodine (-I).

[0038] Atoms, moieties or groups described herein may be unsubstituted or substituted, as valence permits, unless otherwise specified. The term "optionally substituted" refers to substituted or unsubstituted.

[0039] The present disclosure is not limited to the above-mentioned substituent examples.

[0040] "Salt" herein refers to salts formed by the reaction of an acid (eg, a compound of the present invention) with a base, including organic or inorganic bases, such as sodium hydroxide, potassium hydroxide, amines, alkylamines, and the like.

[0041] The term "solvate" refers to a compound form produced by the association of a compound with a solvent through a dissolution reaction. Physical association may include hydrogen bonds. Traditional solvents include water, methanol, ethanol, acetic acid, dimethyl sulfoxide (DMSO), tetrahydrofuran (THF), diethyl ether, and the like. The compounds described herein may be prepared in a crystalline form or a solvated form. Suitable solvates include pharmaceutically acceptable solvates, as well as stoichiometric solvates and non-stoichiometric solvates. In some cases, solvates may be isolated, for example, when one or more solvent molecules are contained in the crystal lattice of a crystalline solid. "Solvates" include solution-phase solvates and isolatable solvates.

[0042] It should be noted that if the stereochemistry of a structure or a portion thereof is not indicated in bold or dashed, it means that the structure or portion of the structure should be interpreted as covering its entire stereochemistry. In addition, any atom in a diagram or chemical formula that appears to have insufficient valence is presumed to have sufficient hydrogen atoms attached to satisfy the valence requirement.

[0043] Stereoisomers that are not mirror images of each other are called "diastereomers", and those that are non-superimposable are called "enantiomers". When a compound has an asymmetric center, for example, bonded to four different groups, a pair of enantiomers is produced. An enantiomer is characterized by the absolute configuration of its asymmetric center, and is designated as right- or left-racemic (i.e., as a (+) or (-)-isomer) by the R- and S-ordering rules of Cahn and Prelog, or by the polarization of the plane of rotation of the molecule. Chiral compounds can exist alone or as a mixture. When a mixture contains equal proportions of enantiomers, it is called a "racemic mixture".

[0044] Unless otherwise indicated, a "therapeutically effective amount" of a compound is an amount of the compound sufficient to produce a therapeutic effect on the treatment or management of a disease or to delay one or more symptoms of the disease. A therapeutically effective amount of a compound is an amount of the compound that, when used alone or in combination with other agents, produces a therapeutic effect on the treatment or management of a disease or to delay one or more symptoms of the disease. A "therapeutically effective amount" includes an amount sufficient to improve the overall treatment of a disease, alleviate or avoid symptoms, or enhance the therapeutic effect of another therapeutic agent.

[0045] Unless otherwise indicated, a "prophylactically effective amount" of a compound is an amount of the compound sufficient to prevent a disease or prevent the recurrence of one or more symptoms of the disease. A prophylactically effective amount of a compound is an amount of the compound that, when used alone or in combination with other agents, can prevent the recurrence of a disease or one or more symptoms of the disease. A "prophylactically effective amount" includes an amount sufficient to improve the overall prevention of a disease, alleviate or avoid symptoms, or enhance the prophylactic effect of another therapeutic agent.

[0046] Unless otherwise specified, "treat", "treating" or "treatment" means any action taken by a patient suffering from a particular disease to lessen the severity or one or more symptoms of the disease or to delay the progression of the disease.

[0047] As used herein, "subject" or "patient" are used interchangeably and mean mammals (including humans) that can be treated with the compounds of the present disclosure. The "mammals" refer to all members of the class Mammalia, including humans, primates, domestic animals and livestock (e.g., rabbits, pigs, sheep, cattle), as well as zoo animals, animals used for sports or pets; and rodents (e.g., mice and rats). Furthermore, unless the sex is explicitly indicated, the term "subject" or "patient" includes both males and females. Therefore, "subject" or "patient" includes any mammal that benefits from the treatment methods of the present disclosure. Examples of "subjects" or "patients" include, but are not limited to: humans, rats, mice, guinea pigs, monkeys, pigs, goats, cattle, horses, dogs, cats, birds, and fowl. In a preferred embodiment, the subject is a human.

[0048] As used herein, "about" generally refers to within 10%, 5%, 1% or 0.5% of a given value or range. Alternatively, the term "about" means that the actual value falls within the acceptable standard error of the mean value, as determined by one of ordinary skill in the art to which the invention pertains. Except for the experimental examples, or unless otherwise expressly stated, it is understood that all ranges, quantities, values ​​and percentages used herein (e.g., to describe the amount of material, the length of time, the temperature, the operating conditions, the ratio of quantities or the angle of reflection) are modified by "about". Therefore, unless otherwise stated to the contrary, the numerical parameters disclosed in this specification and the accompanying patent claims are approximate values ​​and may be changed as needed. At least these numerical parameters should be understood as the indicated significant digits and the values ​​obtained by applying the general rounding method.

[0049] As used herein, the singular forms "a," "an," and "the" include plural forms as well, unless the context clearly indicates otherwise.

[0050] 2. Novel Iduronidase Stabilizer

[0051] Therefore, the primary object of the present disclosure is to provide a compound of formula (I), a pharmaceutically acceptable salt, solvate or stereoisomer thereof, in, n is an integer between 0 and 2; X1 is O or -NH; X2 is O, -NH or -NR a , where R a It is C 1-10 alkyl, Y is H or in m and p can be 0 or 1 respectively; X3 is O, -NH, methylene or -CH2(C 1-10 )alkyl; and A is an aryl group, a heteroaryl group, or a heterocyclic group, each of which may or may not have one or more substituents selected from halogen, hydroxyl, amine, and phosphate.

[0052] According to a preferred embodiment of the present disclosure, in the compound of formula (I), n is 1, X1 is O, X2 is -NH, and Y is H.

[0053] According to certain preferred embodiments of the present disclosure, the compound has a structure of formula (II): in, X1 is O or -NH; X2 is O, -NH or -NR a , where R a It is C 1-10 alkyl; and R1, R2 and R3 can be H or phosphate, respectively.

[0054] According to certain embodiments of the present disclosure, the compound of formula (II) may be any of the following:

[0056] According to a preferred embodiment of the present disclosure, the compound of formula (II) is

[0057] The compounds of the present disclosure have one or more stereocenters and can therefore exist as racemic mixtures of mirror image isomers or mixtures of non-mirror image isomers. Therefore, the present invention also encompasses pure stereo compounds of these compounds, as well as mixtures thereof. The desired mirror image isomer can be isolated from the racemic mixture using high performance liquid chromatography (HPLC) or the desired mirror image isomer can be separated from the racemic mixture by any appropriate method (e.g., using an optically active splitting agent). Depending on the optical properties of the splitting agent selected, one of the two mirror image isomers can be isolated in the form of an insoluble salt with high yield and high optical purity, while the other mirror image isomer remains in the solution in a soluble state.

[0058] The present invention therefore further encompasses mixtures of stereoisomers of the disclosed compounds, as well as configurational isomers (eg, cis- and trans-isomers, independent of the double bond) of the disclosed compounds (stereoisomerically pure or mixtures thereof).

[0059] 3. Purpose

[0060] The present invention also encompasses a method of treating or preventing a subject suffering from mucopolysaccharidosis type I (MPSI), comprising administering to the subject a therapeutically effective amount or a prophylactically effective amount of a compound of formula (I) of the present invention before, after, or simultaneously with administering to the subject recombinant human α-iduronidase (rh-α-DUA).

[0061] The dosage of the compound of formula (I) of the present invention is preferably between 0.01 mg and 5000 mg per day, for example 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82 2, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 96, 97, 98, 99, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520 20、530、540、550、560、570、580、590、600、610、620、630、640、650、660、670、680、690、700、710、720、730、740、750、760、770、780、790、800、810、820、830、840、850、860、870、880、890、900、910、920、930、940、950、960、970、980、990、1,000、1,100、1,200、1,300、1,40 0, 1,500, 1,600, 1,700, 1,800, 1,900, 2,000, 2,100, 2,200, 2,300, 2,400, 2,500, 2,600, 2,700, 2,800, 2,900, 3,000, 3,100, 3,200, 3,300, 3,400, 3,500, 3,600, 3,700, 3,800, 3,900, 4,000, 4,100, 4,200, 4,300, 4,400, 4,500, 4,600, 4,700, 4,800, 4,900, 5,000 mg. The dosage of the compound of formula (I) of the present invention is preferably between 0.1 mg and 2500 mg per day, for example, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69 ,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,96,97,98,99,100,110,120,130,140,150,160,170,180,190,200,210,220,230,240,250,260,270,280,290,300,310,320,33 0、340、350、360、370、380、390、400、410、420、430、440、450、460、470、480、490、500、510、520、530、540、550、560、570、580、590、600、610、620、630、640、650、660、670、680、690、700、710、720、730、740、750、760、770、780、 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, 1,000, 1,100, 1,200, 1,300, 1,400, 1,500, 1,600, 1,700, 1,800, 1,900, 2,000, 2,100, 2,200, 2,300, 2,400, 2,500 mg. The dosage of the compound of formula (I) of the present invention is preferably between 1 mg and 1000 mg per day, for example 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62 2, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 96, 97, 98, 99, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 2 20、230、240、250、260、270、280、290、300、310、320、330、340、350、360、370、380、390、400、410、420、430、440、450、460、470、480、490、500、510、520、530、540、550、560、570、580、590、600、610、 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, 1,000 mg.

[0062] The daily dosage of the compound of formula (I) of the present invention can be divided into one or more daily dosages, for example, twice or three times a day. For example, a daily dosage of 1000 mg can be divided into two daily dosages of 500 mg each time. It should be noted that each dosage is composed of one or more pharmaceutical forms, for example, a 500 mg dosage can be composed of two dosages of 250 mg each.

[0063] The dosage, route and dosage schedule of the compound of formula (I) will depend on the indication to be treated, prevented or managed, as well as factors such as the patient's age, sex and condition. The roles played by the aforementioned factors are well known to those skilled in the art and can be determined through routine experiments.

[0064] According to a preferred embodiment, in formula (I), X is O, Y is H, and the combined administration of the compound of the present invention and recombinant human α-iduronidase (rh-α-DUA) can increase IDUA activity and reduce the amount of HS in a subject.

[0065] 4. Pharmaceutical formula

[0066] The present disclosure also encompasses pharmaceutical compositions that may be suitable for use with rh-α-DUA to treat or prevent mucopolysaccharidosis type I (MPSI).

[0067] In certain embodiments, the compound of formula (II) of the present invention is formulated into a pharmaceutical composition together with one or more pharmaceutically acceptable adjuvants. The compound of formula (II) of the present invention accounts for about 0.1% to 99% of the total weight of the pharmaceutical composition. In certain embodiments, the compound of formula (II) of the present invention accounts for at least 1% of the total weight of the pharmaceutical composition. In a specific embodiment, the compound of formula (II) of the present invention accounts for at least 5% of the total weight of the pharmaceutical composition. In other embodiments, the compound of formula (II) of the present invention accounts for at least 10% of the total weight of the pharmaceutical composition. In certain embodiments, the compound of formula (II) of the present invention accounts for at least 25% of the total weight of the pharmaceutical composition.

[0068] Particular pharmaceutical compositions are suitable for oral, transmucosal (via the nasal cavity, sublingual, intravaginal, buccal or intrarectal), injection (e.g., subcutaneous, intravenous, perfusion, intramuscular or intraarterial), or transdermal single dosage forms. Examples of suitable dosage forms include, but are not limited to, tablets, peeled tablets, capsules (e.g., elastic gelatin soft capsules), tablets, lozenges, lozenges, dispersions, suppositories, ointments, pastes, muds, powders, dressings, creams, plasters, solutions, patches, aerosols (e.g., nasal sprays or inhalants), gels. Examples of liquid dosage forms suitable for oral or transmucosal administration include, but are not limited to suspensions (aqueous or non-aqueous liquid suspensions, emulsions of oil in water or emulsions of water in oil), solutions, and elixirs. Liquid dosage forms suitable for injection can be sterile solids (e.g., crystalline or amorphous compounds) that can be reconstituted into a liquid dosage form.

[0069] The formulation selected should be suitable for the route of administration used. For example, oral drugs need to have an enteric coating to protect the compound from being destroyed by stomach acid. Similarly, the formulation may also contain ingredients that can help deliver the active ingredient to the target area of ​​action. For example, the compound can be administered in the form of liposomes to protect it from being destroyed by enzymes and to help deliver it into the circulatory system and across the cell membrane to the location of the desired action in the cell.

[0070] Poorly soluble drugs can be incorporated into liquid dosage forms (including reconstituted dosage forms) using solubilizers, emulsifiers and surfactants (e.g., α-cyclodextrin or β-cyclodextrin), and non-aqueous solvents. Examples of such non-aqueous solvents include, but are not limited to, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, dimethyl sulfoxide, biocompatible oils (e.g., cottonseed oil, walnut oil, corn oil, olive oil, castor oil, Oil, and sesame oil), glycerol, tetrahydrofurfuryl alcohol (THFA), polyethylene glycol, fatty acid esters of sorbitol and mixtures of the aforementioned compounds (e.g., DMSO: corn oil), fats such as egg phosphatidylcholine (EPC), soybean phosphatidylcholine (SPC), 1,2-dioleoylphosphatidylcholine (DOPC), 1,2-distearoylphosphatidylcholine (DSPC), cholesterol, dipalmitoylphosphatidylcholine (DPPC), and PEG-2000. According to a preferred embodiment, the compound of formula (I) is prepared with fats and oils into a liposome dosage form suitable for oral or injection.

[0071] The composition, shape and form of the dosage form will depend on the final application. For example, the amount of active ingredient contained in the acute treatment dosage form will be much higher than that in the chronic treatment dosage form. Similarly, the amount of active ingredient contained in the injectable dosage form will be much lower than that in the oral dosage form. Those skilled in the art should be able to easily infer the changes in other matters required for these dosage forms of the present invention.

[0072] 4.1 Oral Dosage Form

[0073] Suitable forms of the pharmaceutical compositions of the present invention for oral administration include, but are not limited to, tablets (e.g., chewable tablets), half tablets, capsules, and liquids (e.g., syrups). Such dosage forms contain a predetermined amount of active ingredients and can be prepared using conventional methods.

[0074] Oral dosage forms are typically prepared by mixing the active ingredient with at least one excipient in accordance with conventional pharmaceutical formulations, with appropriate excipients selected depending on the intended route of administration.

[0075] Tablets and capsules are the most advantageous dosage forms due to the ease of use of oral dosage forms. Depending on the needs, the outer layer of the tablet can be coated with standard solution or non-solution technology. It can be made by traditional pharmaceutical methods. Generally speaking, the desired pharmaceutical composition or dosage form is made by uniformly mixing the active ingredient with a liquid carrier, a very fine solid carrier, or both, and then shaping it into the desired shape. Disintegrants can also be added to solid dosage forms to facilitate rapid dissolution. Lubricants can also be mixed into dosage forms (such as tablets).

[0076] 4.2 Parenteral Dosage Forms

[0077] Parenteral dosage forms can be administered by a variety of routes, including, but not limited to, intravenous, intramuscular or intra-arterial routes. Because this route of administration bypasses the patient's own defense system against pathogens, such dosage forms are usually prepared in a sterile state or can be stored in a sterile state before use. Parenteral dosage forms include, but are not limited to, solutions that can be injected immediately, dry powders that can be dissolved or suspended in a pharmaceutically acceptable injection carrier, suspensions that can be injected immediately, or emulsions.

[0078] Examples of carriers that can be used as parenteral dosage forms are well known to those skilled in the art. Examples of such carriers include, but are not limited to, sodium chloride solution, Ringer's solution, and glucose; examples of water-miscible carriers include, but are not limited to, ethanol, polyethylene glycol, and polypropylene glycol; examples of non-solvent carriers include, but are not limited to, oils, corn oil, cottonseed oil, peanut oil, sesame oil, ethyl oleate, isopropyl myristate, and benzyl benzoate.

[0079] 4.3 Transdermal, surface application and oral mucosal dosage forms

[0080] Transdermal, topical and oral mucosal dosage forms include, but are not limited to, eye drops, sprays, aerosols, creams, lotions, ointments, gels, solutions, emulsions, suspensions or other conventional forms. Transdermal dosage forms also include so-called "reservoir" or "matrix" patches that can be applied to the skin or worn for a period of time to allow the desired amount of active ingredients to penetrate into the skin.

[0081] The carriers and other materials that can be used to prepare transdermal, topical and oral mucosal dosage forms are well known to those with ordinary knowledge in this field, and the appropriate carrier can be selected according to the type of tissue on which the specific pharmaceutical composition is intended to be used.

[0082] Depending on the body part to be treated, other ingredients may be used before, at the same time, or after the active ingredient of the present invention is administered. For example, a penetration enhancer may be used to help deliver the active ingredient into the tissue.

[0083] The pH of the pharmaceutical composition or dosage form can be adjusted or the organization of the pharmaceutical composition can be used to adjust the pH of the pharmaceutical composition or dosage form as desired to improve the delivery efficiency of one or more active ingredients. Similarly, the polarity, ionic strength, or tension of the solvent carrier can also be adjusted to improve the delivery efficiency of the active ingredient. Stearate compounds can also be added to the pharmaceutical composition or dosage form to change the hydrophilicity or hydrophobicity of one or more active ingredients to improve the delivery efficiency. Accordingly, stearate compounds can be used as a fat carrier for the formulation, or an emulsifier or interface active agent, as well as an absorption promoter or a skin penetration promoter. Different salts, hydrates, or solvates of the active ingredient can be used to adjust the properties of the resulting composition.

[0084] 5. Kit

[0085] The present disclosure also encompasses kits that can be used to treat or prevent MPS1 in an individual.

[0086] The kit according to the present disclosure includes at least one first container containing the compound of formula (I); and a second container containing rh-α-IDUA; and instructions for use, providing the user with descriptive text on how to use the kit. The instructions for use can be in the form of a manual, videotape, CD, VCD, or DVD. Examples of containers include, but are not limited to, vials, test tubes, etc.

[0087] The following will illustrate the content of the present invention through implementation modes (only for the purpose of illustrating the present invention, not for limiting the scope of the present invention). Although these implementation modes are typical implementation modes, those with ordinary skills in the relevant technical field should be able to use other methods and technologies to replace the implementation modes.

[0088] Example

[0089] Materials and Methods

[0090] Cell culture

[0091] Each cell used herein was cultured in a medium supplemented with 10% fetal bovine serum (FBS), penicillin (100 units / ml), and streptomycin (100 μg / ml) at 37° C. in a humidified atmosphere of 5% CO 2 .

[0092] IDUA activity inhibition assay

[0093] The test compound was mixed with human rh-α-IDUA ( The final concentration was 1.2 nM) and the fluorescent substrate (4-MU-IdoA,) were mixed together in a buffer solution (50 mM NaOAc, 150 mM NaCl) at a final concentration of 100 μM at pH 3.5 and then incubated in a 384-well microplate at 37°C for 30 minutes. Finally, the stop solution (500 mM Na2CO3, pH 10.8) was added and the fluorescence intensity of the product at an emission wavelength of 460 nm after excitation at an excitation wavelength of 355 nm was read. The raw fluorescence intensity must first be subtracted from the background value (i.e., the fluorescence emitted from the solution itself). After the compounds that can inhibit the activity of human rh-α-IDUA enzyme are screened, they are further tested to determine the IC 50 and K i value.

[0094] Example 1 Chemical Synthesis of Compounds of Formula (I)

[0095] The compound of formula (I) of the present invention is synthesized according to the steps shown in Schemes 1-5.

[0096] 1.1 IdoA-type C-glycoside 12

[0097] The synthesis reaction began with the preparation of several grams of intermediate 8, which was prepared from D-glucuronolactone (7) by the 4-step method described by Moffett (JAm Chem Soc 1954, 2813 (12), 3310-3315). C-glycosylation of intermediate 8 with trimethylsilyl silane allowed the separation of the first isomers 9 and 10 in 38% and 34% yields, respectively. The chirality and configuration of the two compounds were determined by NMR, and the results showed that compound 9 had 4 The C1 chair configuration, while compound 10 remains as a configurational isomer. Next, the propenyl group at the C-1 position of IdoA-type C-glycoside 9 is converted into a primary amine 11 with an N-protecting group by Lemieux-Johnson oxidation and reductive amination, and then the C-glycoside 12 is obtained after deprotection.

[0098] Scheme 1: Preparation of IdoA-type C-glycoside 12 (CIdoA 12)

[0099] Compound 12 1 H NMR (600MHz, D2O): δ1.63–1.73(m,1H),2.02–2.10(m,1H),3.05(ddd,J=13.2,7.6,6.0Hz,1H),3.07–3.1 5(m,2H),3.33(dd,J=9.3Hz,1H),3.33–3.40(m,1H),3.57(dd,J=9.6,6.5Hz,1H),4.23(d,J=6.5Hz,1H). 13 C NMR(150MHz,D2O)δ176.4,74.8,73.7,73.0,71.9,70.3,36.8,26.8.[C8H 15 NO6+H] + 222.0972, actual value 222.0968.

[0100] 1.2 Diastereoisomers 15a and 15b

[0101] According to the method described by Tashiro et al. (Bioorganic Med. Chem 2013, 21(11), 3066-3079), compound 13 was prepared from D-glucose. Then, compound 13 was condensed with benzylhydroxylamine to obtain N-benzyl-N-glycoside hydroxylamine 14 (87%). After removing the protective group of the silyl group on the 6th carbon of compound 13, it was successfully subjected to AllMgCl addition reaction to produce several grams of adduct. According to NMR analysis, it can be seen that the adduct is a mixture composed of a mixture in a ratio of 1:3. This diastereomeric mixture can be separated into compounds 15a (a small amount, a yield of about 15%) and 15b (the main compound, a yield of 39%).

[0102] Scheme 2: Preparation of diastereoisomers 15a and 15b

[0103] Alternatively, compounds 15a and 15b can be synthesized using the steps disclosed in Scheme 3, wherein compound 13 is condensed with benzylamine to obtain N-benzyl-N-glycosidamine 18 (84%). Compound 18 is then subjected to a diastereoselective addition reaction of AllMgBr to successfully produce an adduct of compounds 15a and 15b in a ratio of 5:1.

[0104] Scheme 3: Another method for stereoselective preparation of diastereoisomers 15a and 15b

[0105] 1.3 CIdoADNJ 23

[0106] Compound 15b was N-Boc protected, and then the oxygen atom was protected with a methoxymethyl acetal group, and then the protecting group on the silyl group was removed with TBAF to obtain compound 19 (yield of 76% after 3 steps). Then, Swern oxidation, Pinnick oxidation, Steglich esterification, and removal of the N-Boc protecting group were performed in sequence to convert compound 19 to compound 20 (yield of 42% after 4 steps). Compound 20 was methansulfonylated with MsCl at 100°C in the presence of activated molecular sieves to generate iminosugar 21 with N-benzyl protection and a methyl ester group on the 6th carbon in 66% yield. Compound 23 was synthesized from iminosugar 21 according to the similar steps disclosed in Scheme 2 to generate CIdoA 12 from compound 9 (yield of 39% after 4 steps).

[0107] Scheme 4: Preparation of CIdoADNJ 23 from diastereoisomer 15b

[0108] Compound 23 1 H NMR (600MHz, D2O): δ1.98–2.09(m,1H),2.25–2.34(m,1H),3.08–3.19(m,2H),3.49(dt,J=7.5,7.0Hz,1 H), 3.54 (dd, J = 7.6Hz, 1H), 3.60 (dd, J = 7.4Hz, 1H), 3.90 (dd, J = 7.6, 4.7Hz, 1H), 4.15 (d, J = 4.7Hz, 1H). 13 C NMR(150MHz,D2O)δ170.5,72.4,70.1,68.3,55.3,54.6,36.4,27.3.HRMS calcd for[C8H 16 N2O5+H] + 221.1132, actual value 221.1130.

[0109] 1.4CIdoA 27 and CIdoADNJ 28a-c

[0110] After obtaining compounds 12 and 23, they can be coupled to the primary amines of compounds 12 and 23 by forming an amide bond using substituent reagents 24-26 with negatively charged phosphate groups, and then the protecting groups can be removed to generate CIdoA27a-c and CIdoADNJ 28a-c.

[0111] Scheme 5: Preparation of compounds 27a-c and 28a-c

[0112] Compound 27a 1 H NMR (600MHz, D2O): δ1.5–1.6(m,1H),1.9–2.0(m,1H),3.1(t,J=8.8Hz,1H),3.1–3.2(m,1H),3.2–3.3(m,1H),3. 5(s,2H),3.6(t,J=8.9Hz,1H),3.6–3.7(m,2H),4.4(d,J=6.2Hz,1H),7.1(d,J=8.3Hz,2H),7.2(d,J=8.4Hz,2H). 13 CNMR(151MHz,D2O)δ174.5,173.3,163.0(q,J=35.4Hz),151.1,130.5,130.4,120 .7,120.7,116.3(q,J=291.7Hz),74.6,73.7,73.4,72.6,69.9,41.7,36.3,29.9. 31P NMR(202MHz,D2O)δ-2.6.HRMScalcd for[C 16 H 22 NO 11 PH] - 434.0858, actual value 434.0833

[0113] Compound 27b 1 H NMR (600MHz, D2O): δ1.5–1.6(m,1H),1.9–2.0(m,1H),3.1–3.2(m,2H),3.3(dt,J=14.1,6.9Hz,1H),3.5(s,2H),3.6 (t,J=8.9Hz,1H),3.6–3.7(m,2H),4.4(d,J=6.1Hz,1H),7.0–7.0(m,2H),7.0(d,J=8.5Hz,1H),7.3(t,J=7.8Hz,1H). 13 C NMR(151MHz,D2O)δ174.1,173.0,162.9(q,J=35.5Hz),152.0,136.4,130.1,125.1, 121.3, 119.2, 116.2 (q, J = 291.4Hz), 74.6, 73.6, 73.2, 72.6, 69.8, 42.2, 36.4, 29.9. 31 P NMR(202MHz,D2O)δ-2.8.HRMS calcd for[C 16 H 22 NO 11 PH] - 434.0858, actual value 434.0837.

[0114] Compound 27c 1 H NMR (600MHz, D2O): δ1.5–1.6(m,1H),1.9–1.9(m,1H),3.1(t,J=8.9Hz,1H),3.2(dt,J=13.1,6.3Hz,1H),3.3(dt,J=13. 6,6.6Hz,1H),3.6(s,2H),3.6(t,J=9.0Hz,1H),3.6–3.7(m,2H),4.3(d,J=6.0Hz,1H),7.0–7.1(m,1H),7.2–7.3(m,3H). 13CNMR(151MHz,D2O)δ174.1,173.2,163.0(q,J=35.8Hz),150.5,131.3,128.9,126.1, 124.3, 120.1, 116.3 (q, J = 291.2Hz), 74.7, 73.6, 73.3, 72.6, 70.0, 37.3, 36.4, 29.8. 31 P NMR(202MHz,D2O)δ-2.8.HRMS calcd for[C 16 H 22 NO 11 PH] - 434.0858, actual value 434.0833.

[0115] Compound 28a 1 H NMR (600MHz, D2O): δ1.8–1.9(m,1H),2.1–2.2(m,1H),3.2–3.3(m,2H),3.4–3.5(m,1H),3.5(s,2H),3.6(t,J=5.9H z,1H),3.8(t,J=5.7Hz,1H),4.1(t,J=4.7Hz,1H),4.3(d,J=3.9Hz,1H),7.1(d,J=8.2Hz,2H),7.2(d,J=8.1Hz,2H). 13 CNMR(151MHz,D2O)δ175.5,169.4,162.9(q,J=35.7Hz),151.0,130.5,130.4,120 .8,120.7,116.2(q,J=291.4Hz),70.6,69.1,68.1,55.1,54.1,41.5,35.6,28.2. 31 P NMR(202MHz,D2O)δ-2.7.H RMS calcd for[C 16 H 23 N2O 10 PH] - 433.1018, actual value 433.0994.

[0116] Compound 28b 1H NMR (600MHz, D2O): δ1.8–1.9(m,1H),2.1–2.2(m,1H),3.2–3.4(m,2H),3.4–3.5(m,1H),3.6(t,J=5.8Hz,1 H),3.8(t,J=5.8Hz,1H),4.1(t,J=4.9Hz,1H),4.3(d,J=3.7Hz,1H),7.0–7.0(m,3H),7.3(t,J=8.2Hz,1H). 13 C NMR(151MHz,D2O)δ175.1,169.4,162.9(q,J=35.2Hz),152.0,136.3,130.1,125 .1,121.0,116.2(q,J=292.0Hz),70.6,69.1,68.1,55.1,54.2,42.0,35.6,28.2. 31 P NMR(202MHz,D2O)δ-2.6.HRMS calcdfor[C 16 H 23 N2O 10 PH] - 433.1018, actual value 433.0995.

[0117] The yield of compound 28c was 31%. 1 H NMR (600MHz, D2O): δ1.9–1.9(m,1H),2.1–2.2(m,1H),3.3–3.3(m,1H),3.3–3.3(m,1H),3.5(d,J=6.6Hz,1H),3.6 (s,1H),3.7(t,J=5.1Hz,1H),3.8–3.8(m,1H),4.1–4.1(m,1H),4.3–4.3(m,0H),7.1–7.1(m,1H),7.2–7.3(m,4H). 13 C NMR(151MHz,D2O)δ175.1,166.9,162.9,150.4,131.7,129.0,126.0,124 .4,119.9,117.3,115.3,70.7,69.1,68.2,55.3,54.1,37.5,35.6,28.1. 31 P NMR(202MHz,D2O)δ-2.9.HRMS calcd for[C 16 H 23 N2O 10 PH] - 433.1018, actual value 433.0993.

[0118] Example 2 Characteristic Analysis of the Compounds of Example 1

[0119] 2.1 Analysis of IDUA inhibitory activity

[0120] In this example, the ability of each compound synthesized in Example 1 to inhibit the activity of human rh-α-IDUA was evaluated, and the IC of each compound was determined using the fluorescent matrix 4-MU-IdoA. 50 , the results are shown in Table 1.

[0121] IC of CIdoA analogs 27a-c 50 The values ​​were all in the lower micromolar range, indicating that these compounds were more potent than the CIdoADNJ analogs 28a-c (whose IC 50 The value is about 250μM) can better inhibit the activity of human rh-α-IDUA. IC 50 The value decreased from 6.7 μM (compound 12) to 1.0 μM (compound 27c), indicating that coupling with a negatively charged phosphate group with a specific orientation can improve the ability of the compound to inhibit IDUA activity, so compound 27c is the strongest inhibitor in the present disclosure. As for the CIdoADNJ series analogs, compound 28c is significantly better than other compounds in the series.

[0122] Table 1 The ability of compounds 12, 27a-c, 23 and 28a-c to inhibit the activity of human rh-α-IDUA a NI means that the inhibitory activity is less than 10% at a concentration of 250 μM. b % inhibition at 250 μM.

[0123] 2.2α-IDUA stabilizer

[0124] In this embodiment, the ability of each compound synthesized in Example 1 to stabilize α-IDUA enzyme activity as a stabilizer was evaluated in two MPSI cell lines (ie, GM01391 and GM02846, each cell line lacking IDUA enzyme activity).

[0125] Accordingly, GM01391 cells were treated with rh-α-IDUA (0.1 nM) and compounds 12, 27a-c (100 μM) or rh-α-IDUA alone for 1 day, and then the cells were washed for 1 day. After the cells were harvested, lysed, and incubated with a fluorescent substrate, IDUA activity was measured. The results are shown in Figure 1 middle.

[0126] When cells were treated with rh-α-IDUA alone, the previously insufficient IDUA activity of the cells was significantly increased. In addition, compounds 12 and 27b increased the IDUA activity of the cells by approximately 1.4 and 1.6 times, respectively (relative to rh-α-IDUA alone) (Figure 1, (A)). In contrast, in cells co-treated with compound 27c, the IDUA activity showed a moderate decrease, which is presumably because compound 27c itself is an inhibitor of rh-α-IDUA. In addition, when cells were co-treated with compound 27a, it was found that the degree of improvement in IDUA activity was limited.

[0127] In order to confirm whether CIdoA analogs 12, 27a or 27b are potential IDUA stabilizers, a dose-related experiment was performed. The results showed that in the GM01391 cell line, the combined use of rh-α-IDUA (1nM) and compound 12 (500μM) increased its IDUA activity by about 1.7 times (compared with rh-α-IDUA treatment alone); as for the combined use of rh-α-IDUA (1nM) and compound 27a (500μM), its IDUA activity was significantly inhibited ( Figure 1 , (B)).

[0128] The combined use of rh-α-IDUA (1 nM) and compound 12 to treat GM01391 cells can increase the IDUA activity of the cells, and the degree of activity increase is dose-dependent (relative to rh-α-IDUA treatment alone), indicating that compound 12 can stabilize rh-α-IDUA and improve the ability of cells to absorb rh-α-IDUA ( Figure 1 , (C)). In addition, when the concentration of rh-α-IDUA was increased to 1 nM, the dose dependence of compound 12 was more obvious.

[0129] The time course of combined treatment with rh-α-IDUA (1 nM) and compound 12 showed that compound 12 still had the ability to enhance IDUA activity even after the cells were washed for 8 days.

[0130] Generally speaking, MPS patients lack lysosomal enzymes (including IDUA) that can degrade GAGs, which leads to the accumulation of GAGs in the body. Therefore, monitoring the reduction of GAGs can more directly evaluate the effect of co-administering protein stabilizers to enhance the efficacy of protein drugs, rather than measuring the activity of MPDS-related enzymes. As a result, we established a method to quantitatively detect HS (a GAG stored in excess in MPSI patients) to evaluate the potential therapeutic effect of compound 12 on MPSI patients.

[0131] HS was extracted from the treated cells and chemically cleaved into disaccharides as a bioreleasable marker of HS, which can be measured by LC-MS / MS (with a chemically synthesized novel disaccharide as an internal standard). This cell-based HS measurement method was used to quantify the CIdoA analog 12. Compared with rh-α-IDUA alone, the combined use of compound 12 and rh-α-IDUA to treat GM01391 cells can increase the amount of HS accumulated in GM01391 cells, and this increase in the amount of decrease is statistically significant ( Figure 1 , (D)). Similar results were also observed in GM02846 cells treated with compound 12 and rh-α-IDUA. Compound 12 could enhance the activity of rh-α-IDUA, and the increase in IDUA activity was dose-dependent with the dosage of compound 12 ( Figure 2 , (A)); Compared with the use of rh-α-IDUA alone, the combined use of compound 12 and rh-α-IDUA can significantly reduce the accumulation of HS ( Figure 2 , (B)).

[0132] In general, the cell analysis of IDUA activity test and quantitative analysis of the amount of HS in GM01391 and GM02846 cells demonstrated that compound 12 is a stabilizer of IDUA and has the potential to treat MPSI.

[0133] Although specific embodiments of the present invention are disclosed in the above implementation modes, they are not intended to limit the present invention. A person having ordinary knowledge in the technical field to which the present invention belongs may make various changes and modifications without departing from the principles and spirit of the present invention. Therefore, the scope of protection of the present invention shall be based on that defined by the accompanying patent application scope.

Claims

1. A compound having the structure of formula (I) or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, in, n is an integer between 0 and 2; X1 is O or -NH; X2 is O, -NH or -NR a , where R a It is C 1-10 alkyl; Y is H or in m and p can be 0 or 1 respectively; X3 is S, O or -NH; X4 is O, -NH, methylene or -CH2(C 1-10 )alkyl; and A is an aryl group, a heteroaryl group, or a heterocyclic group, each of which may or may not have one or more substituents selected from halogen, hydroxyl, amine, and phosphate.

2. The compound of claim 1 or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein in formula (I), n is 1, X1 is O, X2 is -NH, and Y is H.

3. The compound according to claim 1 or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein the compound has a structure of formula (II): in, X1 is O or -NH; X2 is O, -NH or -NR a , where R a It is C 1-10 alkyl; and R1, R2 and R3 can be H or phosphate, respectively.

4. The compound according to claim 3 or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein the compound is any of the following:

5. The compound according to claim 4 or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein the compound is 6. A method of treating a subject suffering from mucopolysaccharidosis type I (MPSI), comprising administering to the subject a compound of claim 1 or a pharmaceutically acceptable salt, solvate or stereoisomer thereof before, during or after administering to the subject a therapeutically effective amount of recombinant human α-iduronidase.

7. The method of claim 6, wherein in formula (I), n is 1, X1 is O, X2 is -NH, and Y is H.

8. The method of claim 6, wherein the compound has the structure of formula (II) in, X1 is O or -NH; X2 is O, -NH or -NR a , where R a It is C 1-10 alkyl; and R1, R2 and R3 can be H or phosphate, respectively.

9. The method of claim 8, wherein the compound is any of:

10. The method of claim 8, wherein the compound is 11. The method of claim 6, wherein the individual is a human.